AOD-9604 vs Semaglutide

AOD-9604 and semaglutide represent two fundamentally different approaches to weight loss — separated by a significant gap in clinical evidence, regulatory status, and legal access. Semaglutide is an FDA-approved medication supported by Phase III trials showing 14.9%–17.4% mean weight loss at 68 weeks across multiple populations. AOD-9604 failed all Phase IIa clinical trials, was never advanced to Phase III, and is currently prohibited for compounding under FDA interim policy. For athletes, the choice is simpler: AOD-9604 is banned under the WADA 2026 Prohibited List; semaglutide is not.

Key Takeaways

• Semaglutide holds FDA approval across four formulations — Wegovy, Ozempic, Rybelsus, and Oral Wegovy; AOD-9604 holds no FDA approval for any indication
• AOD-9604 failed all Phase IIa clinical trials for weight loss and was discontinued by Metabolic Pharmaceuticals in 2007; semaglutide produced 14.9% mean body weight reduction at 68 weeks in the STEP 1 Phase III trial (Wilding et al., NEJM, 2021; PMID: 33567185)
• The WADA 2026 Prohibited List classifies AOD-9604 under Section S2.2.3 as a banned growth hormone fragment, prohibited both in and out of competition; semaglutide is not on the WADA Prohibited List
• The FDA’s PCAC recommended against including AOD-9604 on the 503A Bulks List at its December 4, 2024 meeting, citing immunogenicity risk and insufficient human safety data; AOD-9604 compounding is currently prohibited
• Oral Wegovy received FDA approval in December 2025 and is available at $149/month for lower doses through NovoCare Pharmacy — narrowing the cost gap with grey-market AOD-9604 substantially

PeptideRx rates the evidence for semaglutide (weight management) as Grade A (multiple Phase III RCTs with consistent results, FDA approval). AOD-9604 is not gradeable for weight loss — clinical development was terminated at Phase IIa after efficacy failure; no Phase III data exists.

Before you start Semaglutide is a prescription medication requiring physician evaluation before use, including screening for thyroid C-cell tumor history (black box warning) and pancreatitis history (contraindication). AOD-9604 is an unapproved research chemical — currently prohibited for compounding under FDA interim policy and banned under WADA rules for competitive athletes. Consult a licensed physician before making any decisions about either compound.

Legal and Regulatory Status

The regulatory gap between these two compounds is the most consequential fact in this comparison.

Semaglutide FDA approvals

Novo Nordisk has received four separate FDA approvals for semaglutide-based products:

Brand	Approval year	Primary indication	Route	Approved dosing
Ozempic	2017	Type 2 diabetes; CV risk reduction	Weekly injection	0.5 mg, 1 mg, 2 mg
Rybelsus	2019	Type 2 diabetes	Daily tablet	7 mg, 14 mg
Wegovy	2021	Chronic weight management; CV risk	Weekly injection	1.7 mg, 2.4 mg
Oral Wegovy	2025	Chronic weight management	Daily tablet	1.5 mg, 4 mg, 9 mg, 25 mg

Wegovy’s indication was extended in March 2024 to include cardiovascular risk reduction in adults with established heart disease and obesity or overweight — supported by the SELECT trial’s 20% reduction in major adverse cardiovascular events (MACE) across 17,604 participants (Lincoff et al., NEJM, 2023; PMID: 37952131).

AOD-9604 regulatory status

AOD-9604 has never received FDA approval for obesity treatment, weight management, or any other indication. In September 2023, the FDA added AOD-9604 to Category 2 of its interim 503A bulks list, citing immunogenicity risk, peptide-related impurity concerns, and insufficient human safety data. The nominator subsequently withdrew its nomination in September 2024. The FDA’s Pharmacy Compounding Advisory Committee reviewed AOD-9604 at its December 4, 2024 public meeting and recommended against inclusion on the permanent 503A Bulks List, citing the same safety concerns. AOD-9604 compounding is currently prohibited under FDA interim policy.

WADA status

Athlete warning: The WADA 2026 Prohibited List (in force January 1, 2026) classifies AOD-9604 explicitly under Section S2.2.3 as a growth hormone fragment, alongside hGH 176-191. This class is prohibited both in and out of competition under the broader S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Athletes subject to testing under any WADA-signatory federation — professional, Olympic, Paralympic, or amateur — will receive an Adverse Analytical Finding if AOD-9604 is detected. Semaglutide is not on the WADA Prohibited List and is permitted for medical use with a valid physician prescription.

Learn more about are peptides legal in the US — the 2026 updated guide.

Understanding Semaglutide Brand Options

Semaglutide is not a single product. Novo Nordisk’s portfolio spans four distinct FDA-approved formulations, each with a specific indication, delivery route, and pricing pathway.

For a direct comparison with AOD-9604’s weight-loss positioning, Wegovy (injectable) and Oral Wegovy (tablet) are the relevant semaglutide comparators — both carry FDA approval specifically for chronic weight management, the same indication AOD-9604’s developers pursued.

Oral Wegovy launched commercially in January 2026 following its December 2025 FDA approval. A 64-week clinical trial in over 300 participants (OASIS-4) found oral semaglutide 25 mg produced an average 16.6% body weight loss in those who completed treatment — consistent with results from injectable semaglutide trials (Novo Nordisk, OASIS-4 results, 2025). Oral Wegovy starts at $149/month for doses of 1.5 mg and 4 mg through NovoCare Pharmacy and GoodRx-affiliated pharmacies.

How They Work: Mechanism Comparison

Semaglutide suppresses appetite through GLP-1 receptor activation — a mechanism validated through Phase III clinical outcomes. AOD-9604 was designed to stimulate fat metabolism directly, but this mechanism was never validated in successful human trials.

Semaglutide mechanism

GLP-1 (glucagon-like peptide-1) is a natural incretin hormone released by intestinal L-cells after eating. Semaglutide mimics GLP-1’s structure and binds GLP-1 receptors in the brain, pancreas, and digestive system. Three therapeutic effects result:

Appetite suppression (primary mechanism): GLP-1 receptor activation in the hypothalamus reduces hunger signals and increases satiety. Participants in the STEP clinical program reduced caloric intake substantially from baseline, contributing to the 14.9%–17.4% mean weight reductions observed at 68 weeks.

Delayed gastric emptying: Semaglutide slows food transit from the stomach to the small intestine, prolonging the sensation of fullness after meals.

Glucose-dependent insulin secretion: Semaglutide stimulates insulin release in response to elevated blood glucose, supporting glycemic control in patients with type 2 diabetes — without causing dangerous blood sugar drops on its own.

AOD-9604 proposed mechanism

AOD-9604 consists of amino acids 177–191 from the C-terminal region of human growth hormone, with an additional N-terminal tyrosine residue added to improve stability during synthesis. Metabolic Pharmaceuticals designed it to stimulate lipolysis (breakdown of stored triglycerides) and inhibit lipogenesis (new fat cell formation) in adipose tissue — without activating the IGF-1 pathway associated with full-length growth hormone, which carries insulin resistance and soft-tissue overgrowth risks.

The lipolysis and lipogenesis mechanisms remain theoretical. AOD-9604 did not produce significant weight loss in any Phase IIa clinical trial. The proposed fat-targeting mechanism was not validated in humans.

The mechanistic distinction matters: semaglutide achieves weight loss primarily by reducing caloric intake through appetite suppression — a pathway confirmed across multiple large trials. AOD-9604 aimed to target fat metabolism directly, but its proposed pathway produced no measurable outcome in clinical testing.

Clinical Evidence: Phase III Success vs Phase IIa Failure

Key takeaways

• STEP 1: Semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks vs 2.4% placebo (N=1,961; Wilding et al., NEJM, 2021; PMID: 33567185)
• STEP 1, 3, 4, and 8 combined: mean weight reductions ranged from 14.9%–17.4% at 68 weeks across participants without type 2 diabetes
• SELECT cardiovascular trial: Semaglutide reduced MACE by 20% vs placebo over 33 months in 17,604 patients with cardiovascular disease and obesity (Lincoff et al., NEJM, 2023; PMID: 37952131)
• AOD-9604: Failed all Phase IIa trials for weight loss; development discontinued by Metabolic Pharmaceuticals in 2007; no Phase III trials ever initiated; no FDA regulatory submission ever filed

Semaglutide STEP trial program

The Semaglutide Treatment Effect in People with Obesity (STEP) clinical program enrolled thousands of participants across multiple Phase III randomized controlled trials:

• STEP 1: 14.9% mean weight loss at 68 weeks vs 2.4% placebo (N=1,961)
• STEP 2: 9.6% loss in people with type 2 diabetes at 68 weeks
• STEP 3: 16% loss combined with intensive behavioral therapy
• STEP 4: Significant weight regain confirmed after discontinuation — GLP-1 medications function as ongoing therapy
• STEP 5: 15.2% loss sustained at 104 weeks, confirming long-term effectiveness

The SELECT cardiovascular outcomes trial enrolled 17,604 adults with preexisting cardiovascular disease and obesity or overweight, without diabetes. Semaglutide 2.4 mg weekly reduced MACE — cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke — by 20% relative to placebo over a mean exposure of 33 months (hazard ratio 0.80; 95% CI 0.72–0.90). This outcome supported the March 2024 FDA approval extension of Wegovy for cardiovascular risk reduction.

AOD-9604 clinical failure

Metabolic Pharmaceuticals conducted Phase IIa clinical trials of AOD-9604 for obesity treatment in the early 2000s. None demonstrated statistically significant weight loss compared to placebo. The development program was discontinued in 2007 before any Phase III investment began. AOD-9604 was never submitted to the FDA for regulatory review.

Semaglutide progressed through the full pharmaceutical approval pathway: Phase III success, regulatory submission, FDA approval, and post-market surveillance accumulating more than seven years of real-world safety data. AOD-9604 was terminated at Phase IIa.

Learn more about peptides vs HGH: which is better for anti-aging.

Side Effects and Safety Profile

Semaglutide (well-characterized)

Semaglutide has a well-characterized side-effect profile based on seven-plus years of post-approval surveillance and data from multiple large trials.

Side effect	Frequency across STEP trials	Notes
Nausea	20–40%	Most common during dose escalation; typically decreases over time
Vomiting	15–30%	Improves as body adjusts to titration
Diarrhea	20–30%	Reducing high-fat meals helps
Constipation	10–20%	Adequate hydration and fiber intake help

Study drug discontinuation due to adverse events occurred in 16.6% of the semaglutide group vs 8.2% in the placebo group in the SELECT trial (Lincoff et al., NEJM, 2023).

Semaglutide carries a black box warning for thyroid C-cell tumors based on rodent studies — human relevance remains unknown. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Pancreatitis risk and gallstone formation are additional recognized adverse events requiring clinical monitoring.

AOD-9604 (very limited data)

Short-term human trial data for AOD-9604 reported minimal adverse events — mild injection-site redness and temporary tingling in some participants. The FDA’s December 2024 PCAC review explicitly cited immunogenicity risk and peptide-related impurity concerns as substantive safety issues. No long-term safety data exist for AOD-9604 because the development program was terminated before comprehensive long-term trials were initiated. The FDA specifically cited “insufficient safety-related information” as a reason for recommending against AOD-9604’s inclusion on the permanent 503A Bulks List.

No standard monitoring protocol exists for AOD-9604. Semaglutide has an established prescribing infrastructure — standardized dose escalation protocols, contraindication screening, and monitoring guidelines developed over seven-plus years of clinical use.

Learn more about peptide side effects: what the clinical research actually shows.

Cost and Insurance Access

Semaglutide pricing (2026)

Brand	List price	NovoCare self-pay	Insurance coverage
Wegovy (injectable)	$1,349/month	$349/month	Prior authorization required; many commercial plans exclude obesity indications
Ozempic	~$998/month	~$349/month	Generally covered for type 2 diabetes
Oral Wegovy	$1,349/month	$149/month (1.5 mg, 4 mg doses)	Prior authorization required for weight-loss indication
Rybelsus	~$900/month	Not specified	Generally covered for type 2 diabetes

Insurance coverage for semaglutide products is strongest when prescribed for type 2 diabetes (Ozempic, Rybelsus). Weight-loss indications (Wegovy, Oral Wegovy) require prior authorization under most commercial plans, and many plans exclude obesity medications entirely. Oral Wegovy’s $149/month self-pay price makes semaglutide more accessible than at any previous point.

AOD-9604 pricing

Grey-market sources and research chemical suppliers charge approximately $50–$150/month for AOD-9604. No insurance plan covers it — no FDA-approved product exists. Quality and purity are not subject to regulatory oversight, and the FDA’s December 2024 PCAC concerns about peptide-related impurities apply directly to grey-market sources where Certificate of Analysis and HPLC purity standards are not enforced by any regulatory authority.

The cost-benefit picture is not straightforward. AOD-9604’s lower monthly cost does not account for its unproven efficacy, unknown safety profile, compounding prohibition, and zero insurance eligibility. Oral Wegovy’s $149/month self-pay option narrows the price gap substantially while providing FDA approval, Phase III evidence, and a known safety profile.

Learn more about how to get a peptide prescription: step by step.

Head-to-head: Which Performs Better for Fat Loss?

Attribute	AOD-9604	Semaglutide (Wegovy / Oral Wegovy)
FDA approval	None — no indication approved	Yes — chronic weight management (Wegovy, Oral Wegovy)
WADA status	Banned — S2.2.3 (Growth Hormone Fragments), in and out of competition	Not prohibited — permitted with physician prescription
Highest trial phase reached	Phase IIa — terminated after efficacy failure	Phase III — multiple completed RCTs
Proven weight loss	No — no significant weight loss in any trial	Yes — 14.9%–17.4% mean reduction at 68 weeks (STEP trials)
Long-term human safety data	None — development terminated before long-term trials	Yes — 7+ years post-approval surveillance
Monthly cost (self-pay)	$50–$150 (grey market, unregulated quality)	$149 (Oral Wegovy, lower doses); $349 (injectable Wegovy) via NovoCare
Insurance access	Zero coverage	Eligible with prior authorization for weight-loss indications
Compounding access	Currently prohibited under FDA interim policy	Separate 503A compounding guidance for licensed pharmacies

For athletes subject to drug testing under any WADA-signatory federation, semaglutide is the only legal option. AOD-9604 will produce a positive test and disqualification. For non-athletes seeking proven, physician-supervised weight management, semaglutide provides an evidence-based pathway that AOD-9604 does not.

Can you Combine AOD-9604 and Semaglutide?

No — and there is no clinical rationale that supports doing so.

No clinical trials have studied AOD-9604 and semaglutide together. Whether combining these two proposed mechanisms would produce additive, neutral, or harmful effects in humans has never been investigated. Given AOD-9604’s lack of proven efficacy and active compounding prohibition, no clinical rationale supports adding it to semaglutide therapy. Adding an unproven compound with an unknown safety profile to a validated, FDA-approved medication introduces unknown risk without established benefit.

The combination also does not resolve WADA prohibition for athletes. Semaglutide is permitted under WADA rules. AOD-9604 is banned. Using both compounds does not exempt an athlete from the AOD-9604 ban.

Anyone considering concurrent use of multiple compounds with metabolic effects should consult a licensed physician who can assess individual risk factors, evaluate potential interactions, and advise within the bounds of current regulatory guidance.

The Bottom Line

Semaglutide is an FDA-approved medication with Phase III clinical validation, a seven-year post-approval safety record, and a $149/month self-pay entry point through Oral Wegovy. AOD-9604 is an unapproved research chemical that failed its clinical development program, is currently prohibited for compounding, and is banned for competitive athletes under WADA rules. There is no scenario in which AOD-9604 represents a safer or more evidence-backed alternative to semaglutide for weight management — the evidence gap is not a matter of degree but of category. If cost has been a barrier to accessing prescription GLP-1 medications, Oral Wegovy’s $149/month NovoCare pricing makes this the right time to revisit that conversation with a licensed physician.

Frequently Asked Questions

Is AOD-9604 legal to use in the United States?

No regulatory pathway exists for legal human use. AOD-9604 holds no FDA approval, is prohibited for compounding under FDA interim policy, and is sold through grey-market suppliers as a “research chemical” labeled “not for human use.” Possession is not explicitly criminalized, but no approved medical use exists and regulatory risk applies to any medical or commercial use of the compound.

Will athletes fail drug tests if using AOD-9604?

Yes. The WADA 2026 Prohibited List classifies AOD-9604 under Section S2.2.3 as a banned growth hormone fragment, prohibited both in and out of competition. Athletes in professional sports, amateur competitions, and “natural” bodybuilding federations will receive an Adverse Analytical Finding if AOD-9604 is detected. Semaglutide is not on the WADA Prohibited List and is permitted for medical use with a physician prescription.

Does insurance cover semaglutide for weight loss?

Coverage varies by indication and insurance plan. Semaglutide prescribed for type 2 diabetes (Ozempic, Rybelsus) generally receives good reimbursement. Wegovy and Oral Wegovy (weight-loss indications) require prior authorization, and many commercial plans currently exclude obesity medications. Self-pay patients can access injectable Wegovy at $349/month and Oral Wegovy at $149/month (lower doses) through NovoCare Pharmacy. AOD-9604 carries zero insurance coverage.

What is GLP-1 and how does it relate to semaglutide?

GLP-1 (glucagon-like peptide-1) is a natural incretin hormone released by the small intestine after eating. It activates receptors in the hypothalamus to suppress appetite, stimulates glucose-dependent insulin secretion from the pancreas, and slows gastric emptying to prolong satiety. Semaglutide is a synthetic GLP-1 receptor agonist that mimics GLP-1’s molecular structure and activates these same receptor pathways, with a longer half-life that enables once-weekly dosing for injectable formulations.

How is Oral Wegovy different from injectable Wegovy?

Oral Wegovy (semaglutide 25 mg tablet) received FDA approval in December 2025 as the first oral GLP-1 approved for weight loss in the United States. A 64-week trial in over 300 participants (OASIS-4) demonstrated an average 16.6% body weight loss in participants who completed treatment. Oral Wegovy is taken once daily, requires no injections, and starts at $149/month for lower doses (1.5 mg and 4 mg) through NovoCare. Injectable Wegovy (2.4 mg) is administered once weekly and costs $349/month through NovoCare.

What are the most common side effects of semaglutide?

Gastrointestinal adverse events are the most commonly reported. Nausea occurs in 20–40% of patients, vomiting in 15–30%, diarrhea in 20–30%, and constipation in 10–20%. These effects most commonly occur during dose escalation and typically decrease as the body adjusts. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, or prior pancreatitis.

Consult a licensed physician to determine whether semaglutide is appropriate for your health profile and to discuss which formulation fits your clinical and access needs.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131
3. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4). JAMA. 2021;325(14):1414-1425. PMID: 33755728
4. Ryan DH, Lingvay I, Deanfield J, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30:2049-2057
5. FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act — Interim list update, September 2023. Available at: FDA.gov
6. FDA. Pharmacy Compounding Advisory Committee (PCAC) Meeting, December 4, 2024 — AOD-9604-related bulk drug substances. Briefing document and meeting transcript. Available at: FDA.gov
7. WADA. 2026 Prohibited List — World Anti-Doping Code International Standard. World Anti-Doping Agency. Published September 11, 2025; in force January 1, 2026
8. FDA. FDA approves new indication for drug containing ingredient in Ozempic, Wegovy to reduce risk of serious heart problems in adults with obesity or overweight. FDA News Release, March 8, 2024. Available at: FDA.gov
9. Novo Nordisk. FDA approves Wegovy (semaglutide) tablet 25 mg for weight management. Press release, December 2025
10. GoodRx Health. GoodRx now offers Novo Nordisk’s cash price for the launch of the Wegovy pill. Business Wire, January 5, 2026

Disclaimer: The information on this page is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. PeptideRx is not a licensed medical provider and does not offer clinical consultations. Peptide therapy and prescription medications such as semaglutide require a physician evaluation and valid prescription from a licensed healthcare provider. No compound discussed on this page is endorsed for any specific health outcome. Regulatory status information reflects conditions as of March 2026 and is subject to change. Legal and compounding status for AOD-9604 is based on FDA interim policy and PCAC recommendations as of the date noted above. Always consult a licensed physician before starting, stopping, or modifying any medical treatment or supplement protocol.